Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 13 | 2021 | 368 | 3.740 |
Why?
|
| Chromatography, High Pressure Liquid | 18 | 2021 | 548 | 3.040 |
Why?
|
| Riluzole | 8 | 2023 | 22 | 2.420 |
Why?
|
| Spinal Cord Injuries | 7 | 2023 | 374 | 2.060 |
Why?
|
| Neuroprotective Agents | 6 | 2023 | 215 | 1.730 |
Why?
|
| Gastric Bypass | 3 | 2019 | 81 | 1.400 |
Why?
|
| Paclitaxel | 6 | 2020 | 1996 | 1.370 |
Why?
|
| Mycophenolic Acid | 3 | 2017 | 148 | 1.250 |
Why?
|
| Cervical Cord | 1 | 2023 | 19 | 0.920 |
Why?
|
| Neck Injuries | 1 | 2023 | 32 | 0.910 |
Why?
|
| Veratrum Alkaloids | 2 | 2019 | 32 | 0.870 |
Why?
|
| Immunosuppressive Agents | 3 | 2017 | 1375 | 0.840 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 156 | 0.820 |
Why?
|
| Polyethylene Glycols | 7 | 2019 | 615 | 0.810 |
Why?
|
| Plasma | 2 | 2017 | 158 | 0.700 |
Why?
|
| Camptothecin | 2 | 2019 | 517 | 0.680 |
Why?
|
| Obesity, Morbid | 2 | 2019 | 224 | 0.680 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 37 | 0.660 |
Why?
|
| Polymyxin B | 6 | 2015 | 53 | 0.660 |
Why?
|
| Chromatography, Liquid | 6 | 2021 | 342 | 0.660 |
Why?
|
| Bile | 1 | 2018 | 81 | 0.650 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2018 | 151 | 0.620 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 120 | 0.590 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 235 | 0.570 |
Why?
|
| Drug Combinations | 1 | 2018 | 621 | 0.570 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2007 | 852 | 0.560 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 6009 | 0.540 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 85 | 0.530 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 849 | 0.490 |
Why?
|
| Calcium Chloride | 1 | 2014 | 23 | 0.490 |
Why?
|
| Arginine Vasopressin | 1 | 2014 | 60 | 0.490 |
Why?
|
| Limit of Detection | 3 | 2019 | 78 | 0.450 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 218 | 0.450 |
Why?
|
| Epinephrine | 1 | 2014 | 255 | 0.440 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 151 | 0.440 |
Why?
|
| Prodrugs | 3 | 2019 | 217 | 0.430 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 330 | 0.430 |
Why?
|
| Drug Stability | 6 | 2018 | 105 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2021 | 2063 | 0.420 |
Why?
|
| Rats | 9 | 2021 | 6086 | 0.410 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 577 | 0.390 |
Why?
|
| Intensive Care Units | 1 | 2015 | 717 | 0.360 |
Why?
|
| Copper Radioisotopes | 2 | 2019 | 31 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 6550 | 0.340 |
Why?
|
| Half-Life | 6 | 2021 | 259 | 0.340 |
Why?
|
| Biological Availability | 5 | 2021 | 214 | 0.330 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2014 | 84 | 0.320 |
Why?
|
| Length of Stay | 1 | 2015 | 1900 | 0.310 |
Why?
|
| Administration, Oral | 5 | 2021 | 1544 | 0.310 |
Why?
|
| Hemolysis | 1 | 2007 | 127 | 0.300 |
Why?
|
| Calibration | 2 | 2018 | 337 | 0.300 |
Why?
|
| Animals | 25 | 2021 | 59536 | 0.290 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2017 | 81 | 0.290 |
Why?
|
| Temperature | 3 | 2018 | 506 | 0.270 |
Why?
|
| Obesity | 1 | 2018 | 2884 | 0.270 |
Why?
|
| Solubility | 6 | 2007 | 242 | 0.270 |
Why?
|
| Biological Assay | 2 | 2017 | 177 | 0.270 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 750 | 0.260 |
Why?
|
| Tissue Distribution | 4 | 2019 | 875 | 0.260 |
Why?
|
| Infusions, Intravenous | 4 | 2016 | 1382 | 0.240 |
Why?
|
| Spinal Cord | 2 | 2018 | 690 | 0.240 |
Why?
|
| Liposomes | 2 | 2018 | 684 | 0.230 |
Why?
|
| Solvents | 3 | 2018 | 66 | 0.220 |
Why?
|
| Etoposide | 2 | 1999 | 870 | 0.220 |
Why?
|
| Reference Standards | 3 | 2016 | 339 | 0.220 |
Why?
|
| Weight Loss | 2 | 2019 | 627 | 0.210 |
Why?
|
| Injections, Intravenous | 4 | 2018 | 573 | 0.210 |
Why?
|
| Male | 19 | 2023 | 123000 | 0.210 |
Why?
|
| Sodium Chloride | 2 | 2014 | 156 | 0.210 |
Why?
|
| Kenya | 1 | 2021 | 46 | 0.200 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 21 | 0.200 |
Why?
|
| Cell Survival | 1 | 2007 | 3045 | 0.190 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2018 | 45 | 0.180 |
Why?
|
| Calcitriol | 1 | 2020 | 127 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 5 | 2015 | 2992 | 0.180 |
Why?
|
| Excipients | 3 | 2010 | 17 | 0.180 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 249 | 0.180 |
Why?
|
| Nanoparticles | 2 | 2019 | 554 | 0.180 |
Why?
|
| Infant, Premature | 2 | 2015 | 787 | 0.180 |
Why?
|
| Humans | 30 | 2023 | 261506 | 0.170 |
Why?
|
| Rosuvastatin Calcium | 1 | 2018 | 43 | 0.170 |
Why?
|
| Propylene Glycol | 1 | 2018 | 10 | 0.170 |
Why?
|
| Glycerol | 1 | 2018 | 99 | 0.160 |
Why?
|
| Simvastatin | 1 | 2018 | 106 | 0.160 |
Why?
|
| Lactones | 1 | 2018 | 94 | 0.160 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2017 | 11 | 0.160 |
Why?
|
| Copper | 1 | 2018 | 165 | 0.150 |
Why?
|
| Serpins | 1 | 2018 | 77 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 344 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 109 | 0.150 |
Why?
|
| Emulsions | 2 | 2007 | 82 | 0.150 |
Why?
|
| Busulfan | 2 | 2000 | 764 | 0.150 |
Why?
|
| Acetates | 1 | 2017 | 105 | 0.150 |
Why?
|
| Vincristine | 1 | 2021 | 1511 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2015 | 2803 | 0.150 |
Why?
|
| Pharmaceutical Solutions | 2 | 2014 | 22 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 5061 | 0.150 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 164 | 0.140 |
Why?
|
| Anisoles | 1 | 2016 | 2 | 0.140 |
Why?
|
| Solid Phase Extraction | 1 | 2016 | 4 | 0.140 |
Why?
|
| Atmospheric Pressure | 1 | 2016 | 8 | 0.140 |
Why?
|
| Exosomes | 1 | 2019 | 253 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 665 | 0.140 |
Why?
|
| Middle Aged | 10 | 2023 | 86204 | 0.140 |
Why?
|
| Eye Proteins | 1 | 2018 | 269 | 0.140 |
Why?
|
| Time Factors | 6 | 2021 | 12926 | 0.140 |
Why?
|
| Linear Models | 1 | 2019 | 1085 | 0.140 |
Why?
|
| Glucuronides | 1 | 2016 | 37 | 0.140 |
Why?
|
| Drug Design | 1 | 2018 | 375 | 0.140 |
Why?
|
| Cholesterol | 1 | 2019 | 658 | 0.140 |
Why?
|
| Serum Albumin | 1 | 2016 | 257 | 0.140 |
Why?
|
| Neoplasms | 2 | 2021 | 15193 | 0.140 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 565 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 6942 | 0.130 |
Why?
|
| Body Temperature Regulation | 1 | 2015 | 38 | 0.130 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 41 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 702 | 0.130 |
Why?
|
| Lipopolysaccharides | 2 | 2019 | 558 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2018 | 825 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 494 | 0.120 |
Why?
|
| Drug Packaging | 1 | 2014 | 13 | 0.120 |
Why?
|
| Sus scrofa | 1 | 2015 | 169 | 0.120 |
Why?
|
| Spectrophotometry | 1 | 2014 | 82 | 0.120 |
Why?
|
| Laser Therapy | 1 | 2018 | 411 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 588 | 0.120 |
Why?
|
| Humidity | 1 | 2014 | 29 | 0.120 |
Why?
|
| Drug Compounding | 1 | 2014 | 70 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1945 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 173 | 0.120 |
Why?
|
| Dopamine | 1 | 2015 | 312 | 0.120 |
Why?
|
| Particle Size | 2 | 2019 | 182 | 0.120 |
Why?
|
| Area Under Curve | 3 | 2019 | 700 | 0.120 |
Why?
|
| Antiemetics | 1 | 2014 | 125 | 0.120 |
Why?
|
| Species Specificity | 1 | 2015 | 777 | 0.110 |
Why?
|
| Female | 17 | 2019 | 141928 | 0.110 |
Why?
|
| Mice | 11 | 2019 | 34495 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 208 | 0.110 |
Why?
|
| Adult | 9 | 2019 | 77950 | 0.110 |
Why?
|
| Teichoic Acids | 1 | 2012 | 13 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.110 |
Why?
|
| Midazolam | 1 | 2012 | 75 | 0.110 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 130 | 0.110 |
Why?
|
| Anesthetics, Intravenous | 1 | 2012 | 73 | 0.100 |
Why?
|
| Models, Animal | 1 | 2015 | 664 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 156 | 0.100 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2012 | 83 | 0.100 |
Why?
|
| Body Fluids | 1 | 2013 | 125 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 2173 | 0.100 |
Why?
|
| Inflammation | 2 | 2019 | 2522 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 4143 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 755 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2018 | 935 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2023 | 2588 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 13310 | 0.090 |
Why?
|
| Pentetic Acid | 2 | 2006 | 48 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2016 | 16273 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.080 |
Why?
|
| Oils | 1 | 2007 | 9 | 0.080 |
Why?
|
| Child | 2 | 2021 | 29154 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 1618 | 0.080 |
Why?
|
| Surface-Active Agents | 1 | 2007 | 41 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 1724 | 0.070 |
Why?
|
| Adolescent | 4 | 2016 | 31252 | 0.070 |
Why?
|
| Quinine | 1 | 1986 | 8 | 0.070 |
Why?
|
| Nicotinic Acids | 1 | 2006 | 33 | 0.070 |
Why?
|
| Ochronosis | 1 | 1986 | 2 | 0.070 |
Why?
|
| Niacin | 1 | 2006 | 61 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 52 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 2638 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2019 | 7226 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 14551 | 0.070 |
Why?
|
| Skin Absorption | 1 | 1984 | 7 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 190 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 482 | 0.060 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.060 |
Why?
|
| Triamcinolone Acetonide | 1 | 1984 | 38 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8223 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5178 | 0.060 |
Why?
|
| Azepines | 1 | 1984 | 124 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2003 | 72 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2006 | 429 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2019 | 4307 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 459 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 7222 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1997 | 585 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 21445 | 0.060 |
Why?
|
| Aged | 4 | 2019 | 70117 | 0.060 |
Why?
|
| Cervical Vertebrae | 2 | 2013 | 205 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2819 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 231 | 0.050 |
Why?
|
| Indoles | 1 | 2006 | 1009 | 0.050 |
Why?
|
| Suspensions | 1 | 2019 | 17 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 1999 | 20 | 0.040 |
Why?
|
| Microscopy, Polarization | 1 | 1999 | 9 | 0.040 |
Why?
|
| 2-Propanol | 1 | 1999 | 10 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1999 | 33 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2019 | 75 | 0.040 |
Why?
|
| Crystallization | 1 | 1999 | 132 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 604 | 0.040 |
Why?
|
| Micelles | 1 | 2018 | 34 | 0.040 |
Why?
|
| Solutions | 1 | 1997 | 104 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2018 | 139 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1997 | 128 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 566 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.040 |
Why?
|
| Polymers | 1 | 2018 | 223 | 0.040 |
Why?
|
| Dogs | 1 | 1997 | 1155 | 0.030 |
Why?
|
| Polymyxins | 1 | 2015 | 19 | 0.030 |
Why?
|
| Water | 1 | 1997 | 361 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 785 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1077 | 0.030 |
Why?
|
| Kinetics | 2 | 2010 | 2049 | 0.030 |
Why?
|
| Gels | 1 | 2014 | 105 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 190 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1293 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1559 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 46 | 0.030 |
Why?
|
| Drug Contamination | 2 | 2010 | 52 | 0.030 |
Why?
|
| Serum | 1 | 2013 | 68 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2013 | 60 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 2314 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 4938 | 0.030 |
Why?
|
| Uremia | 1 | 1983 | 42 | 0.030 |
Why?
|
| Ibuprofen | 1 | 1983 | 56 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 186 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 93 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 3254 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 245 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2012 | 115 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 206 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2013 | 562 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 233 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 2450 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 503 | 0.020 |
Why?
|
| Bordetella bronchiseptica | 1 | 2010 | 5 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2000 | 2238 | 0.020 |
Why?
|
| Refrigeration | 1 | 2010 | 15 | 0.020 |
Why?
|
| Drug Storage | 1 | 2010 | 29 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 703 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 1989 | 39 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1989 | 137 | 0.020 |
Why?
|
| Salicylates | 1 | 1979 | 59 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6207 | 0.020 |
Why?
|
| Apoptosis | 1 | 2003 | 7591 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 4971 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 693 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5317 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 3438 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2000 | 1870 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2023 | 32848 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 1073 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 2352 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 2146 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 1986 | 34 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 2006 | 65 | 0.020 |
Why?
|
| Molecular Probe Techniques | 1 | 2006 | 46 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1986 | 255 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 2203 | 0.020 |
Why?
|
| Malaria | 1 | 1986 | 92 | 0.020 |
Why?
|
| Aspirin | 1 | 1979 | 455 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1983 | 945 | 0.020 |
Why?
|
| Mice, Hairless | 1 | 1984 | 55 | 0.020 |
Why?
|
| Membranes, Artificial | 1 | 1984 | 38 | 0.020 |
Why?
|
| Diffusion | 1 | 1984 | 88 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 305 | 0.020 |
Why?
|
| Silicone Elastomers | 1 | 1984 | 49 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 1082 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 769 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2006 | 1008 | 0.010 |
Why?
|
| United States | 2 | 2013 | 15433 | 0.010 |
Why?
|
| Radioisotopes | 1 | 2003 | 177 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5710 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 3151 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9180 | 0.010 |
Why?
|
| Skin | 1 | 1986 | 1259 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 11965 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 2000 | 211 | 0.010 |
Why?
|
| Acetamides | 1 | 2000 | 113 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2000 | 327 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 465 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 15862 | 0.010 |
Why?
|
| Ultrafiltration | 1 | 1983 | 22 | 0.010 |
Why?
|
| Absorption | 1 | 1983 | 81 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 3001 | 0.010 |
Why?
|
| Veins | 1 | 1983 | 157 | 0.010 |
Why?
|
| Arteries | 1 | 1983 | 274 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 37905 | 0.010 |
Why?
|
| Flame Ionization | 1 | 1979 | 1 | 0.010 |
Why?
|
| Methods | 1 | 1979 | 189 | 0.010 |
Why?
|
| Tablets | 1 | 1979 | 53 | 0.010 |
Why?
|